GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback